LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Hubert Nielly"
  2. AU="Mueller, F."
  3. AU="Kumar, Pooja S"
  4. AU="Ejzak L."
  5. AU="Sisti, M"
  6. AU="White, B."
  7. AU=Gaeta Christopher
  8. AU="Zhou, Tony"
  9. AU=Haji Jumana Yusuf AU=Haji Jumana Yusuf
  10. AU="O'Neill, Anne"
  11. AU="Dima, Maria"
  12. AU="Hu, Jize"
  13. AU="Park, Eun Chan" AU="Park, Eun Chan"
  14. AU="Kwon, DeokKyu"
  15. AU="Szabo, Istvan Adorjan"
  16. AU="Pasdeloup, David"
  17. AU="Baikova, Olga Y"
  18. AU="Woo-Do Lee"
  19. AU="Dubouchaud, Hervé"

Suchergebnis

Treffer 1 - 2 von insgesamt 2

Suchoptionen

  1. Artikel ; Online: Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants

    Camille Chauvin / Laurine Levillayer / Mathilde Roumier / Hubert Nielly / Claude Roth / Anupama Karnam / Srinivasa Reddy Bonam / Anne Bourgarit / Clément Dubost / Aurore Bousquet / Sébastien Le Burel / Raphaële Mestiri / Damien Sene / Joris Galland / Marc Vasse / Matthieu Groh / Mathilde Le Marchand / Camille Vassord-Dang / Jean-François Gautier /
    Nhan Pham-Thi / Christiane Verny / Bruno Pitard / Cyril Planchais / Hugo Mouquet / Richard Paul / Etienne Simon-Loriere / Jagadeesh Bayry / Laurent Gilardin / Anavaj Sakuntabhai

    iScience, Vol 26, Iss 3, Pp 106124- (2023)

    2023  

    Abstract: Summary: Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19) patients has proven its efficacy at the clinical level, there is little evidence supporting the effect of short-term use of interleukin-6 receptor blocking ...

    Abstract Summary: Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19) patients has proven its efficacy at the clinical level, there is little evidence supporting the effect of short-term use of interleukin-6 receptor blocking therapy on the B cell sub-populations and the cross-neutralization of SARS-CoV-2 variants in convalescent COVID-19 patients. We performed immunological profiling of 69 tocilizumab-treated and non-treated convalescent COVID-19 patients in total. We observed that SARS-CoV-2-specific IgG1 titers depended on disease severity but not on tocilizumab treatment. The plasma of both treated and non-treated patients infected with the ancestral variant exhibit strong neutralizing activity against the ancestral virus and the Alpha, Beta, and Delta variants of SARS-CoV-2, whereas the Gamma and Omicron viruses were less sensitive to seroneutralization. Overall, we observed that, despite the clinical benefits of short-term tocilizumab therapy in modifying the cytokine storm associated with COVID-19 infections, there were no modifications in the robustness of B cell and IgG responses to Spike antigens.
    Schlagwörter Health sciences ; Virology ; treatment ; Immunology ; Science ; Q
    Thema/Rubrik (Code) 616
    Sprache Englisch
    Erscheinungsdatum 2023-03-01T00:00:00Z
    Verlag Elsevier
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  2. Artikel ; Online: Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases

    Patrice Cacoub / Arsène Mekinian / Zahir Amoura / Eric Hachulla / Yves Allenbach / Renaud Felten / Anne-Sophie Korganow / Christelle Sordet / Aurélien Guffroy / Xavier Mariette / Christophe Richez / Jacques-Eric Gottenberg / Alain Meyer / Jean Sibilia / Benjamin Terrier / Emmanuel Chatelus / Laurence Bouillet / Marie-Elise Truchetet / Isabelle Melki /
    Divi Cornec / Martin Michaud / Raphaele Seror / Bénédicte Rouvière / Pierre Quartier / Sebastien Ottaviani / Julien Henry / Valérie Devauchelle-Pensec / Claire Larroche / Azeddine Dellal / Marie Desmurs / Mathieu Jouvray / Hubert Nielly / Antoine Poulet / Guillaume Vial / Roland Jaussaud / Boris Bienvenu / Pierre-Yves Jeandel / Jean-François Kleinmann / Emeline Gaigneux / Aurélie Saunier / Amelie Leurs / Aurore Chaudier / Marc Gatfosse / Vincent Andre / Gildas Baulier / Mathieu Ete / Samira Litim-Ahmed-Yahia

    RMD Open, Vol 8, Iss

    data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases)

    2022  Band 2

    Abstract: Objectives To assess the tolerance and efficacy of targeted therapies prescribed off-label in refractory low-prevalence autoimmune and inflammatory systemic diseases.Methods The TATA registry (TArgeted Therapy in Autoimmune Diseases) is a prospective, ... ...

    Abstract Objectives To assess the tolerance and efficacy of targeted therapies prescribed off-label in refractory low-prevalence autoimmune and inflammatory systemic diseases.Methods The TATA registry (TArgeted Therapy in Autoimmune Diseases) is a prospective, observational, national and independent cohort follow-up. The inclusion criteria in the registry are as follows: age >18 years; low-prevalence autoimmune and inflammatory systemic disease treated with off-label drugs started after 1 January 2019.Results Hundred (100) patients (79 women) were enrolled. The median age was 52.5 years (95% CI 49 to 56) and the median disease duration before enrolment was 5 years (3 to 7). The targeted therapies at enrolment were as follows: Janus kinase/signal transducers and activators of transcription inhibitors (44%), anti-interleukin (IL)-6R (22%), anti-IL-12/23, anti-IL-23 and anti-IL-17 (9%), anti-B cell activating factor of the tumour necrosis factor family (5%), abatacept (5%), other targeted treatments (9%) and combination of targeted treatments (6%). 73% of patients were receiving corticosteroid therapy at enrolment (median dose 10 mg/day). The current median follow-up time is 9 months (8 to 10).Safety: 11 serious infections (incidence rate of 14.8/100 patient-years) and 1 cancer (1.3 cancers/100 patient-years) were observed. Two patients died from severe COVID-19 (2.7 deaths/100 patient-years).Efficacy: the targeted treatment was considered effective by the clinician in 56% of patients and allowed, in responders, a median reduction of oral corticosteroids of 15 (9 to 21) mg/day, below 7.5 mg/day in 76% of patients, while 28% discontinued.Conclusion These initial results of the TATA registry confirm the diversity of targeted treatments prescribed off-label in refractory autoimmune diseases and their corticosteroid-sparing effect when effective. Tolerance was acceptable in these refractory patients with a long history of treatment with immunosuppressive drugs.
    Schlagwörter Medicine ; R
    Thema/Rubrik (Code) 610 ; 616
    Sprache Englisch
    Erscheinungsdatum 2022-11-01T00:00:00Z
    Verlag BMJ Publishing Group
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Zum Seitenanfang